Transient receptor potential vanilloid 1 (TRPV1) ion channel is a classic analgesic target, but antagonists of TRPV1 failed in clinical trials due to their side effects like hyperthermia. Here we rationally engineer a peptide s-RhTx as a positive allosteric modulator (PAM) of TRPV1. Patch-clamp recordings demonstrate s-RhTx selectively potentiated TRPV1 activation. s-RhTx also slows down capsaicin-induced desensitization of TRPV1 in the presence of calcium to cause more calcium influx in TRPV1-expressing cells. In addition, our thermodynamic mutant cycle analysis shows that E652 in TRPV1 outer pore specifically interacts with R12 and K22 in s-RhTx. Furthermore, we demonstrate in vivo that s-RhTx exhibits long-lasting analgesic effects in noxious heat hyperalgesia and CFA-induced chronic inflammatory pain by promoting the reversible degeneration of intra-epidermal nerve fiber (IENF) expressing TRPV1 channels in mice, while their body temperature remains unaffected. Our results suggest s-RhTx is an analgesic agent as a PAM of TRPV1.
Mesoporous silica nanoparticles (MSNs) have emerged as cornerstone biomaterials for nanomedicine due to their highly tunable physicochemical properties. This review highlights recent breakthroughs in MSN-based platforms for disease theranostics. We systematically outline fundamental synthesis strategies and detail how surface functionalization-imparting properties such as targeting, stimuli-responsiveness, and biomimicry-transforms MSNs from passive carriers into intelligent theranostic agents. The review then summarizes the major contributions of these engineered platforms across key diagnostic (e.g., advanced imaging) and therapeutic (e.g., targeted drug delivery, dynamic therapies) applications, underscoring their potential in tackling complex diseases. Finally, we address the critical challenges hindering clinical translation, including manufacturing scalability and long-term biocompatibility. We conclude by outlining future directions, such as integration with emerging modalities like immunotherapy, aimed at accelerating the bench-to-bedside transition of MSN-based nanomedicines.